Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


04.02.2019

1 Br J Cancer
1 Eur J Obstet Gynecol Reprod Biol
3 Gynecol Oncol
3 Int J Cancer
1 Int J Gynaecol Obstet
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Br J Cancer

  1. DI GIROLAMO C, Walters S, Gildea C, Benitez Majano S, et al
    Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009-2013? Implications for use of the data in research.
    Br J Cancer. 2018;118:733-737.
    PubMed     Text format     Abstract available


    Eur J Obstet Gynecol Reprod Biol

  2. SONG T, Kim MK, Jung YW, Yun BS, et al
    The role of appendectomy in patients with mucinous borderline ovarian tumors.
    Eur J Obstet Gynecol Reprod Biol. 2018;229:112-116.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  3. MODUGNO F, Goughnour SL, Wallack D, Edwards RP, et al
    Breastfeeding factors and risk of epithelial ovarian cancer.
    Gynecol Oncol. 2019 Jan 25. pii: S0090-8258(19)30060.
    PubMed     Text format     Abstract available

  4. CHOI HJ, Heo JH, Park JY, Jeong JY, et al
    A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Gynecol Oncol. 2019 Jan 25. pii: S0090-8258(19)30045.
    PubMed     Text format     Abstract available

  5. HURLEY RM, Wahner Hendrickson AE, Visscher DW, Ansell P, et al
    53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    Gynecol Oncol. 2019 Jan 24. pii: S0090-8258(19)30058.
    PubMed     Text format     Abstract available


    Int J Cancer

  6. HUANG RL, Chen HJ, Chen LY, Chao TK, et al
    Epigenetic loss of heparan sulfate 3-O-sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis.
    Int J Cancer. 2018 May 7. doi: 10.1002/ijc.31580.
    PubMed     Text format     Abstract available

  7. TRABERT B, Michels KA, Anderson GL, Brinton LA, et al
    Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study.
    Int J Cancer. 2019 Jan 26. doi: 10.1002/ijc.32157.
    PubMed     Text format     Abstract available

  8. BHASKARAN SP, Chandratre K, Gupta H, Zhang L, et al
    Germline variation in BRCA1/2 is highly ethnic-specific: evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.
    Int J Cancer. 2019 Jan 31. doi: 10.1002/ijc.32176.
    PubMed     Text format     Abstract available


    Int J Gynaecol Obstet

  9. DITTO A, Leone Roberti Maggiore U, Bogani G, Martinelli F, et al
    Predictive factors of recurrence in patients with early-stage epithelial ovarian cancer.
    Int J Gynaecol Obstet. 2019 Jan 30. doi: 10.1002/ijgo.12769.
    PubMed     Text format     Abstract available


    PLoS One

  10. HEINZEL A, Marhold M, Mayer P, Schwarz M, et al
    Synthetic lethality guiding selection of drug combinations in ovarian cancer.
    PLoS One. 2019;14:e0210859.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: